Nitric oxide synthase and structure-based inhibitor design.

Area of Science:

• Biochemistry
• Pharmacology
• Neuroscience

Background:

• Nitric oxide synthase (NOS) is central to nitric oxide (NO) biosynthesis, making it a significant drug target.
• Overproduction of NO by neuronal NOS (nNOS) is implicated in neurodegenerative diseases.
• Developing isoform-selective inhibitors is critical to avoid side effects, especially concerning endothelial NOS (eNOS) and its cardiovascular functions.

Purpose of the Study:

• To review the historical development of NOS inhibitors.
• To highlight recent advancements in creating isoform-selective NOS inhibitors.
• To focus on structure-based approaches for inhibitor design.

Main Methods:

• Review of historical data on NOS inhibitor development.
• Analysis of structure-based drug design strategies.
• Examination of challenges in achieving NOS isoform selectivity.

Main Results:

• Identification of NOS isoforms (nNOS, eNOS, iNOS) and their roles.
• Recognition of the difficulty in achieving isoform selectivity due to conserved active site structures.
• Progress in structure-based design for selective NOS inhibitors.

Conclusions:

• Selective inhibition of nNOS is a therapeutic goal for neurodegenerative disorders.
• Achieving selectivity among NOS isoforms, particularly sparing eNOS, is a major hurdle.
• Structure-based approaches offer promising strategies for developing effective and safe NOS inhibitors.